Skip to main content

Table 2 Clinical characteristics of the studied patients

From: Impact of vitamin D level in diabetic people with peripheral neuropathy

Item

Group A (n = 20)

Group B (n = 20)

Group C (n = 20)

Control group (n = 20)

χ2/KWT

p-value

n

%

n

%

n

%

n

%

Duration of DM (years)

 Mean ± SD

8.95 ± 3.42

8.7 ± 3.63

7.6 ± 2.94

3.6 ± 1.2

14.86

0.001* (HS)

 Median (range)

9 (4–15)

8 (3–17)

7 (3–14)

3 (1–6)

The current hypoglycemic drug

 Insulin

10

50%

8

40%

8

40%

9

45%

4.81

0.850 (NS)

 Glimepiride

3

15%

5

25%

6

30%

5

25%

 Gliclazide

6

30%

3

15%

4

20%

3

15%

 Combined preparation

1

5%

4

20%

2

10%

3

15%

Score of neuropathy (TCSS)

 Mean ± SD

12.25 ± 2.14

7.6 ± 1.09

9.70 ± 2.02

0.95 ± 1.19

63.39

0.000* (HS)

 Median (range)

12.5 (9–15)

8(6–9)

9 (7–14)

0.5 (0–4)

Stage of diabetic foot

 Normal foot

12

60%

20

100%

0

0%

20

10

65.11

0.001* (HS)

 Ulcerated

4

20%

0

0%

17

85%

0

0

 Infected

3

15%

0

0%

2

10%

0

0

 Necrotic

1

5%

0

0%

1

5%

0

0

  1. n: number; %: percentage; χ2: Chi-square test; KWt: Kruskal–Wallis test; HS: highly significant; TCSS: Toronto Clinical Scoring System